嶄猟井   
 
Introduction of Clinical Oncology and Cancer Research

  (Formerly Chinese Journal of Clinical Oncology)

  In 2009, Chinese Journal of Clinical Oncology (CJCO) will change its name to Clinical Oncology & Cancer Research (COCR). COCR published bimonthly in English, is sponsored by the Chinese Anti-Cancer Association (CACA). COCR was founded by Professor Xishan Hao (Editor-in-chief) in 2004. The journal is abstracted and indexed in Chemical Abstracts (CA) and Excerpta Medica (EM). The editorial board is composed of 51 well-known international experts in oncology from China, UK, Australia, USA, Canada and Japan. In addition, a team of peer reviewers includes more than 100 experts and invited language editors Dr. John F. Hofert, Dr. Vincent T. D¨Orazio and Roshan Golmohammadi.

  COCR welcomes significant, original studies in all areas of experimental, clinical, translational, epidemiological, and prevention research. Scientific topics include: cell and tumor biology; clinical research; endocrinology; epidemiology; experimental therapeutics, molecular targets and chemical biology; immunology; molecular biology, pathobiology and genetics and prevention. Thus its publication scope covers all subfields of cancer research. All submissions undergo peer review.

  Since its inception in February 2004, COCR has won favorable appraisal from a vast number of authors and readers, with its original topics, fine quality of the articles, and flexible format. The journal is becoming companion for all participants in the field of medical oncology, with creative participation from the scientific community relying on the Chinese edition of CJCO. The staff of the COCR contribute to its individual style and highlight the principle and characteristics of the journal. Under the guidance and support of senior oncologists, COCR will, we hope, provide a way for the English speaking world to learn about Chinese researches in the field of oncology.

  COCR has been making significant progress, in terms of publishing more than 300 articles, in terms of steadily increasing its impact factor in China, and the number of submissions stabilized. We delighted that during 2008 this trend continues. Its main aim is to obtain a ranking position among global leading oncology periodicals. For the near future, COCR¨s goals are to increase the number of submissions and quality of papers, and to try to make the journal more attractive and appealing to contributors and to readers. We are also very concerned with improving the satisfaction of contributors by speeding up the review process and assisting, as much as possible, in the process of revisions of manuscripts before their final acceptance. We will handle the article submission process through the internet in 2009, and this in turn should allow us to accelerate the publication process.

  High priority is given to continuation and enhancement of solicited reviews. We believe that these positive trends, combined with the strong commitment and support from CACA and the Editorial Board, allow us to be optimistic about the future.

  In 2007, COCR developed a new strategy to promote the international outreach of COCR. As part of this strategy, COCR and Springer-Werlag GmbH which is one of the world's premier science publishers announced a newly signed co-publishing agreement. Springer is responsible for the distribution of the printed and electronic version of COCR outside of Mainland China. The five year cooperation is expected to be fruitful for both parties.

  COCR is compared with his excellent peers, COCR is still a boy, a young boy, but COCR is a young boy with great energy, great enthusiasm, great envision and great expectation. We take this opportunity to thank the authors for their interest and trust in COCR and to thank the reviewers, the members of the Editorial Board and the Editors for their efforts and their support during the past 5 years.

  Copyright @ 2009 Chinese Anti-Cancer Association